Group items tagged

Shingles is a type of skin infection that is mainly caused by the reactivation of herpes zoster or chickenpox virus. Two vaccines till now have proven successful at reducing the chances of developing shingles. One is, Zostavax, which consists of a bigger-than-usual dose of the chickenpox vaccine since shingles and chickenpox are caused by the same virus, the varicella virus. The other vaccine is called Shinglesvax, consists of an adult shingles vaccine which has been proven to be effective in preventing younger children and adults from developing shingles. If someone develops shingles after receiving either of these, they need a varicella immune globulin vaccine. The shingles vaccine is made from a weakened chickenpox virus and when used in combination with symptoms specific to shingles, it greatly reduces the risks of developing the infection. However, there is a possibility of developing more serious side effects such as a rash or muscle pain. Rare side effects include feeling faint, nausea, blurred vision, and chest pain. The factor driving the growth of the shingles vaccine market is the increased prevalence of shingles worldwide. Moreover, the rising geriatric population and the high number of launches and approval of shingle vaccines are also estimated to trigger the market growth. For instance, in August 2019, experts from the Université Laval, Québec, and Centre de research du Centre Hospitalier de l'Université de Québec found that the Shingrix vaccine developed by GSK is very effective in terms of cost and treatment than the Zostavax developed by Merck & Co. The overall effectiveness of the vaccine was 97% and has a higher effectiveness rate among the geriatric population. Shingrix right now is the main competitor of Zostavax in the market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/the-global-shingles-vaccine-market.html